Erratum: Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: An fMRI study (Neuropsychopharmacology (2011) 36 (1340-1348) DOI: 10.1038/npp.2011.17);Modulation of auditory and visual processing by delta-9- tetrahydrocannabinol and cannabidiol: An fMRI study

Neuropsychopharmacology

Volumn 36, Issue 7, 2011, Pages 1340-1348

  Winton Brown, Toby T ^a   Allen, Paul ^a   Bhattacharrya, Sagnik ^a   Borgwardt, Stefan J ^a,b   Fusar Poli, Paolo ^a,c   Crippa, Jose A ^d   Seal, Marc L ^a,e   Martin Santos, Rocio ^a,f   Ffytche, Dominic ^a   Zuardi, Antonio W ^d   Atakan, Zerrin ^a   McGuire, Philip K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

auditory; cannabidiol; cannabis; delta 9 tetrahydrocannabinol; sensory; visual

Indexed keywords

CANNABIDIOL; DRONABINOL; PLACEBO;

ADULT; ANXIETY; ARTICLE; ATTENUATION; AUDITORY STIMULATION; BLOOD LEVEL; BRAIN FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEARING; HEARING TEST; HUMAN; INGESTION; INTOXICATION; MALE; MENTAL DISEASE; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEMPORAL CORTEX; TEMPORAL GYRUS; VISION; VISUAL STIMULATION; WERNICKE AREA;

EID: 79956035968     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.58     Document Type: Erratum

References (42)

1. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L (1981). Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37: 1090-1092. (Pubitemid 12179489)
2. Allen P, Laroi F, McGuire PK, Aleman A (2008). The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev 32: 175-191. (Pubitemid 350160963)
3. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P (2009a). Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacol-ogy. Curr Pharm Des 15: 2603-2614.
4. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C et al (2009b). Modulation of mediotem-poral and ventrostriatal function in humans by Delta9-tetra-hydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442-451.
5. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML et al (2008). Neural basis of Delta-9-tetrahydrocanna-binol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966-973.
6. Chesher GB, Bird KD, Jackson DM, Perrignon A, Starmer GA (1990). The effects of orally administered delta 9-tetrahydro-cannabinol in man on mood and performance measures: a dose-response study. Pharmacol Biochem Behav 35: 861-864. (Pubitemid 20129987)
7. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L et al (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417-426. (Pubitemid 38175159)
8. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572. (Pubitemid 38982249)
9. Ffytche DH (2008). The hodology of hallucinations. Cortex 44: 1067-1083.
10. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998). The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1: 738-742. (Pubitemid 128406387)
11. Folstein MF, Luria R (1973). Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3: 479-486.
12. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al (2009). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural acti. Arch Gen Psychiatry 66: 95-105.
13. Green B, Kavanagh D, Young R (2003). Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22: 453-460. (Pubitemid 37496019)
14. Gruber SA, Yurgelun-Todd DA (2005). Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res 23: 107-118. (Pubitemid 40417511)
15. Hall W, Babor TF (2000). Cannabis use and public health: assessing the burden. Addiction 95: 485-490. (Pubitemid 30220244)
16. Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352: 1611-1616. (Pubitemid 28515256)
17. Harpaz Y, Levkovitz Y, Lavidor M (2009). Lexical ambiguity resolution in Wernicke's area and its right homologue. Cortex 45: 1097-1103.
18. Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F (1967). Effects of (F)delta-9-trans-tetrahydrocannabi-nol in man. Psychopharmacologia 11: 184-188.
19. Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM et al (2007). Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol 17: 289-297. (Pubitemid 46156994)
20. Jung-Beeman M (2005). Bilateral brain processes for comprehending natural language. Trends in Cognitive Sciences 9: 512-518. (Pubitemid 41540123)
21. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276. (Pubitemid 18039085)
22. Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U et al (2006). Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydro-cannabinol altered states of consciousness. Schizophr Res 88: 142-150. (Pubitemid 44693257)
23. Leweke FM, Schneider U, Thies M, Münte TF, Emrich HM (1999). Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl) 142: 230-235. (Pubitemid 29200149)
24. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE (1999). Regional cerebral blood flow and deperso-nalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100: 67-75. (Pubitemid 29309200)
25. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G et al (1992). The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 9: 199-213.
26. Mechoulam R, Gaoni Y (1967). Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25: 175-213.
27. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8: 885-895. (Pubitemid 350006219)
28. O'Leary DS, Block RI, Flaum M, Schultz SK, Boles Ponto LL, Watkins GL et al (2000). Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport 11: 3835-3841.
29. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC et al (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26: 802-816. (Pubitemid 34455033)
30. O'Leary DS, Block RI, Koeppel JA, Schultz SK, Magnotta VA, Ponto LB et al (2007). Effects of smoking marijuana on focal attention and brain blood flow. Hum Psychopharmacol 22: 135-148. (Pubitemid 46730582)
31. Oertel V, Rotarska-Jagiela A, van de Ven VG, Haenschel C, Maurer K, Linden DE (2007). Visual hallucinations in schizophrenia investigated with functional magnetic resonance imaging. Psychiatry Res 156: 269-273. (Pubitemid 350116559)
32. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
33. Price CJ, Wise RJ, Warburton EA, Moore CJ, Howard D, Patterson K et al (1996). Hearing and saying. The functional neuro-anatomy of auditory word processing. Brain 119(Part 3): 919-931. (Pubitemid 26237188)
34. Spielberger CG, Lushene RL, R Vagg PR (1983). State-Trait Anxiety Inventory For Adults. Consulting Psychologists Press: Palo Alto, CA.
35. Spitzer RL, Williams JB, Gibbon M, First MB (1992). The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49: 624-629.
36. Tart CT (1970). Marijuana intoxication common experiences. Nature 226: 701-704.
37. Thomas H (1996). A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42: 201-207. (Pubitemid 26356554)
38. Williams SA, Simmons A, Bullmore E, Brammer M (1997). Multiplexed stimuli presentation for functional MRI studies. Neuroimage 3: S41.
39. Willshire D, Kinsella G, Prior M (1991). Estimating WAIS-R IQ from the National Adult Reading Test: a cross-validation. J Clin Exp Neuropsychol 13: 204-216.
40. Woodruff PW, Wright IC, Bullmore ET, Brammer M, Howard RJ, Williams SC et al (1997). Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Am J Psychiatry 154: 1676-1682. (Pubitemid 27516583)
41. Zuardi AW (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.
42. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.